ArticleScientific reports2019
PES1 promotes the occurrence and development of papillary thyroid cancer by upregulating the ERα/ERβ protein ratio.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Comprehensive methylome and transcriptome profiling reveals specific biomarkers for bovine viral diarrhea virus persistent infection in calves.Frontiers in immunology · 2026Article
- Pescadillo ribosomal biogenesis factor 1 as a therapeutic target in tumor immunotherapy.World journal of gastroenterology · 2025Article
- Estrogen Receptors as Key Factors in Carcinogenesis.Biomedicines · 2025Review
- Gut microbiome versus thyroid cancer: Association and clinical implications (Review).Oncology letters · 2025Review
- The SUMOylation and ubiquitination crosstalk in cancer.Journal of cancer research and clinical oncology · 2023Review
- PES1 is a biomarker of head and neck squamous cell carcinoma and is associated with the tumor microenvironment.Cancer medicine · 2023Article
- Pescadillo ribosomal biogenesis factor 1 reduction suppresses tumour growth and renders chemosensitivity of head and neck squamous cell carcinoma.Cancer medicine · 2023Article
- Hormonal Crosstalk Between Thyroid and Breast Cancer.Endocrinology · 2022Review
- RNA-interference screen for p53 regulators unveils a role of WDR75 in ribosome biogenesis.Cell death and differentiation · 2022Article
- The Isoforms of Estrogen Receptor Alpha and Beta in Thyroid Cancer.Frontiers in oncology · 2022Review
- The functional role of Pescadillo ribosomal biogenesis factor 1 in cancer.Journal of Cancer · 2022Review
- Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases.International journal of molecular sciences · 2021Review
- Differential Effects of Estrogen Receptor Alpha and Beta on Endogenous Ligands of Peroxisome Proliferator-Activated Receptor Gamma in Papillary Thyroid Cancer.Frontiers in endocrinology · 2021Article
- Signal Pathway of Estrogen and Estrogen Receptor in the Development of Thyroid Cancer.Frontiers in oncology · 2021Review
- PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer.Journal of experimental & clinical cancer research : CR · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PES1, a BRCT domain-containing protein, has been shown to play a role in modulating the balance and ratio between ERα and ERβ protein, which is involved in the occurrence and development of breast and ovarian cancer. However, its role in connection with the balance and ratio between ERα and ERβ protein in papillary thyroid cancer (PTC) remains unclear. Here, we found that ERα and ERβ were co-expressed in human PTC tissues and cells. ERα promoted and ERβ inhibited the proliferation, invasion and migration of PTC cells. PES1 modulated the balance between ERα and ERβ by elevating the ERα protein level and simultaneously reducing the ERβ protein level, then upregulating the ERα/ERβ protein ratio and promoting the proliferation, invasion and migration of PTC cells. In PTC tissues, PES1 protein level was positively correlated with the ERα protein level and negatively correlated with the ERβ protein level. The PES1 and ERα protein levels were gradually increased and the ERβ protein level was decreased by degree in the occurrence and development of PTC. Increased PES1 and ERα protein levels and decreased ERβ protein level were correlated with the aggressive behaviors of PTC patients such as large tumor size, extrathyroidal extension (ETE), lymph node metastasis (LNM), high BRAFV600E expression and high TNM stage. It is suggested that PES1 promotes the occurrence and development of PTC by elevating the ERα protein level and reducing the ERβ protein level, and then upregulating the ERα/ERβ protein ratio.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.